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Interferon-γ receptor 1 (IFNγR1) deficiency is one of the inborn errors of IFN-γ immunity
underlying Mendelian Susceptibility to Mycobacterial Disease (MSMD). This molecular
circuit plays a crucial role in regulating the interaction between dendritic cells (DCs)
and T lymphocytes, thus affecting DCs activation, maturation, and priming of T cells
involved in the immune response against intracellular pathogens. We studied a girl who
developed at the age of 2.5 years a Mycobacterium avium infection characterized by
disseminated necrotizing granulomatous lymphadenitis, and we compared her findings
with other patients with the same genetic condition. The patient carried a heterozygous
818del4 mutation in the IFNGR1 gene responsible of autosomal dominant (AD) partial
IFNγR1 deficiency. During the acute infection blood cells immunophenotyping showed
a marked reduction in DCs counts, including both myeloid (mDCs) and plasmacytoid
(pDCs) subsets, that reversed after successful prolonged antimicrobial therapy. Histology
of her abdomen lymph node revealed a profound depletion of tissue pDCs, as
compared to other age-matched granulomatous lymphadenitis of mycobacterial origin.
Circulating DCs depletion was also observed in another patient with AD partial
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IFNγR1 deficiency during mycobacterial infection. To conclude, AD partial IFNγR1
deficiency can be associated with a transient decrease in both circulating and tissular
DCs during acute mycobacterial infection, suggesting that DCs counts monitoring might
constitute a useful marker of treatment response.
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INTRODUCTION
Interferon-γ receptor 1 (IFNγR1) deficiency was discovered in
1996 as the first genetic etiology of the Mendelian Susceptibility
to Mycobacterial Disease (MSMD) (1, 2). MSMD is a rare
inherited primary immunodeficiency due to impaired IFN-γ-
mediated immunity that leads to selective predisposition to
clinical disease caused by weakly virulent mycobacteria, such as
bacillus Calmette-Guerin (BCG) vaccines and non-tuberculous
environmental mycobacteria (EM) (3). This condition also
exposes to higher risk of infection from the more virulent
Mycobacterium tuberculosis,Candida spp., Salmonella, and,more
rarely, to other intra-macrophagic bacteria, fungi, or parasites.
Mutations in the IFNGR1 gene account for the altered cell
surface expression of the high affinity ligand-binding chain
of the receptor and impair the cellular response to IFNγ.
IFNGR1 mutations result in five distinct clinical phenotypes
depending on the pattern of inheritance (dominant or recessive),
the impact of the mutation (complete or partial defect) and
the expression of the mutant allele. Patients with autosomal
recessive (AR) complete IFNγR1 deficiency display the most
severe clinical phenotype with life-threatening disseminated
infections starting in early childhood (3). In this form, the
majority are null mutations that prevent the production of
the receptor; alternatively, in-frame deletions and missense
mutations are reported to cause the production of IFNγR1
that, altered in its extracellular domain, in unable to bind
the ligand (3). It has been hypothesized that high levels of
serum IFNγ may be responsible for the high rate of graft
rejection observed in these patients after hematopoietic stem
cell transplantation (HSCT), that currently represents the only
curable treatment (4). In patients with AR partial IFNγR1
deficiency, homozygous mutations include specifically the I87T,
V63G, and M1K mutations: in leukocytes the receptor is
expressed but not responsive to high concentrations of IFNγ. The
clinical outcome of infections and the survival are favorable (5).
Finally, the autosomal dominant (AD) form of partial IFNγR1
deficiency includes heterozygous mutations in the cytoplasmic
domain of the receptor leading to truncated molecule that
accumulates at the cell surface, binds IFNγ, but cannot transduce
the signal. Typically, these patients manifest mycobacterial
disease at an older age (late childhood/adulthood) and are
successfully treated with prolonged antimicrobial treatment (6,
7). The susceptibility to mycobacteria and to other intracellular
opportunistic pathogens is also common to autosomal defects
in IFNGR2, IL12B, IL12RB1, STAT1, ISG15, IRF8 genes, or X-
linked mutations in NEMO and CYBB genes, or in the recently
described signal peptide peptidase-like 2A (SPPL2A), IL12RB2,
and IL23R deficiencies, TYK2 deficiency, or syndromic forms
due to RORγ /RORγT and JAK1 deficiencies (3, 8–10). We
herein report the immunological study of a pediatric patient
with AD partial IFNγR1 deficiency who onset with disseminated




Four µm tissue sections from formalin-fixed and paraffin-
embedded lymph nodes from the patient (PT) and two
age-matched children were used for Hematoxylin and Eosin
staining (H&E) and immunohistochemical staining to CD3
(clone LN10, Leica Biosystems), CD20 (clone L26, Leica
Biosystems), and CD303 (clone 124B3.13, Dendritics) antigens.
Briefly, after appropriate antigen retrival, antibodies were
revealed using Novolink Polymer (Leica Biosystems) followed by
Diaminobenzidine (DAB) and counterstained with hematoxylin.
Sequencing of the IFNGR1 Gene
Informed consent for hematological, immunological, and genetic
tests was obtained from the patient’s parents. The investigation
protocol was approved by the local ethic committee of the Asst
Spedali Civili of Brescia. We adhered to standard biosecurity
and institutional safety procedures. The IFNGR1 gene was
analyzed by Sanger sequencing by using standard techniques.
DNA was isolated from whole blood using QIAamp DNA Blood
Mini Kit (Qiagen). IFNGR1 gene was amplified by PCR and
products were sequenced using BigDye Terminator Kit (Applied
Biosystems). Sequences were analyzed with 310 Genetic Analyzer
(Applied Biosystems).
Expression of IFNγR1 and Phosphorylation
of STAT1 on Monocytes by Flow Cytometry
Assay
IFNγR1 cell-surface expression was assessed on monocytes
(CD14+ cells) by using a standard flow cytometry protocol that
requested a staining of 100 µl of fresh whole blood with PE-
conjugated anti-human IFNγR1 mAb (BD Biosciencies). Blood
samples were acquired using a FACSCalibur flow cytometer
(Becton Dickinson, San Diego, Calif) and analyzed by the
FlowJo software version 7.5 Software (TreeStar, Ashland, Ore).
Cells were fixed and permeabilized, following the manufacturer’s
instructions (BD Biosciences). Similarly, analysis of STAT1
phosphorylation was performed on 100 µl of fresh whole blood
that was left unstimulated or stimulated with IFN-γ (1,000
U/ml for 30min). Blood cells were fixed and permeabilized,
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following the manufacturer’s instructions (Becton Dickinson)
and intracellular staining was performed using a PE-conjugated
anti-human pSTAT1-Tyr-701 mAb (BD Pharmigen). Blood
samples were acquired using a FACSCalibur flow cytometer
and analysis of monocytes (CD14+ cells) pSTAT1 expression
performed by FlowJo software.
Cytokine Detection
Peripheral blood mononuclear cells (PBMCs) were obtained
from EDTA-treated whole blood of the patient and healthy
control by the standard density centrifugation procedure,
in Ficoll Hypaque. Cytokine production was measured in
the supernatants after 24 h of incubation by ELISA using
matched paired Abs specific for IFNα (Mabtech) and CXCL10
(R&D systems).
Immunophenotype Analysis by Flow
Cytometry
Whole blood (100 or 200ml) was stained for immunophenotypic
analysis using a combination of monoclonal antibodies
(mAb) (Becton Dickinson, San Diego, Calif), according
to standard multiparametric flow cytometry protocols, in
order to identify different lymphocytes and DCs subsets.
Blood samples were acquired using a FACSCantoII
flow cytometer (Becton Dickinson) and analyses were
performed with the FlowJo software version 8.8.7 (TreeStar,
Ashland, Ore). Immunological data were compared to
the reference values of the “A. Nocivelli” Institute for
Molecular Medicine of Brescia that performed the analysis,
based on a database obtained from a pool of age-matched
healthy subjects.






Age (years) 2.4 2.9 3.8 5.1
Monocytes
Cells/mmc 230 (285–500) 270 (285–500) 440 (285–500) 630 (285–500)
Total lymphocytes
Cells/mmc 3,350 (1,700–6,900) 5,720 (1,700–6,900) 6,050 (1,700–6,900) 4,990 (1,100–5,900)
T CD3+ Lymphocytes
Cells/mmc 2,569 (900–4,500) 3,106 (900–4,500) 4,761 (900–4,500) 4,091 (700–4,200)
% 76.7 (58.1–78.6) 54.3 (58.1–78.6) 78.7 (58.1–78.6) 82 (59.1–80.9)
CD3+CD4+
Cells/mmc 1,217 (500–2,400) 903 (500–2,400) 2,432 (500–2,400) 1,787 (300–2,000)
% 47.4 (27.3–48.5) 29.1 (27.3–48.5) 51.1 (27.3–48.5) 43.7 (24.9–51.1)
CD3+CD4+ HLA-DR+ % 26.8 (1.4–17.6) 16.4 (1.4–17.6) 13.5 (1.4–17.6) 10.2 (1.4–13.3)
CD3+CD4+ CD45RA+CCR7+ % 61.8 (53.6–81.4) 62 (53.6–81.4) 48.4 (53.6–81.4) 66.9 (37.8–80.3)
CD3+CD4+ CD45RA-CCR7+ % 13 (12.1–24.5) 20.9 (12.1–24.5) 32.8 (12.1–24.5) 18.7 (9.9–41.1)
CD3+CD8+
Cells/mmc 644 (300–1,600) 599 (300–1,600) 928 (300–1,600) 1,288 (300–1,800)
% 25.1 (15–32.7) 19.3 (15–32.7) 19.5 (15–32.7) 31.5 (13.8–31.2)
CD3+CD8+ HLA-DR+% 23.7 (2.1–52) 10.9 (2.1–52) 26.5 (2.1–52) 30.1 (2.3–23.4)
CD3+CD8+ CD45RA+CCR7+% 13.6 (23–85.1) 17.6 (23–85.1) 14.5 (23–85.1) 15.4 (20.3–78.2)
CD3+CD8+ CD45RA-CCR7+% 2.8 (0.2–7.6) 1.7 (0.2–7.6) 3.9 (0.2–7.6) 2.8 (1.7–13.3)
B CD19+ Lymphocytes
Cells/mmc 626 (200–2,100) 2,162 (200–2,100) 1,101 (200–2,100) 698 (200–1,600)
% 18.7 (9.8–28) 37.8 (9.8–28) 18.2 (9.8–28) 14 (8.6–26–3)
CD19+ IgD+CD21hi% 43.9 (40.6–57.9) 61.4 (40.6–57.9) 55.4 (40.6–57.9) 47.5 (37.1–70.2)
CD19+ IgD-CD27+CD21hi% 3.5 (1.8–10.5) 2.1 (1.8–10.5) 3.9 (1.8–10.5) 12.2 (2.4–19.8)
PC CD38hiCD27hiCD20-CD138+% 5.59 (0.11–2.2) 0.32 (0.11–2.2) 4.3 (0.11–2.2) 3.7 (0.06–2.7)
CD3-CD16+CD56+ NK Cells
Cells/mmc 90 (100–1,000) 417 (100–1,000) 115 (100–1,000) 104 (90–900)
% 2.7 (5–28.4) 7.3 (5–28.4) 1.9 (5–28.4) 2.1 (3.3–22.8)
pDC (BDCA2+CD123+CD4+)
% 0.04 (0.16–0.76) 0.01 (0.16–0.76) 0.17 (0.16–0.76) 0.35 (0.16–0.76)
mDC (CD1c+CD4+CD19-CD14-)
% 0.05 (0.18–0.92) 0.05 (0.18–0.92) 0.38 (0.18–0.92) 0.45 (0.18–0.92)
The values out of range are marked in bold numbers.
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Statistical Analysis
Statistical significance of immunological studies was analyzed
by non-parametric two-side Mann– Whitney U-test with 95%
confidence bounds. For all analyses p < 0.05 was considered
statistically significant. Statistical analyses were performed
using GraphPad Prism Version 5.0 (GraphPad Software,
San Diego, CA).
RESULTS
Disseminated Mycobacterial Infection in
Partial Dominant IFNγR1 Deficiency
A 2.5-year-old female (P1) was admitted to the hospital
because of 3 weeks of daily fever (over 38◦C) associated with
fatigue, vomiting and diarrhea. She was born in Italy from
FIGURE 1 | IFNγR1 cell-surface expression and activity in cells of patient heterozygous for 818del4 IFNGR1 mutation. (A) The expression of IFNγR1 molecules
(measured as Mean Fluorescence Intensity, MFI) at the surface of CD14-positive mononuclear blood cells, in the patient (P1) and a healthy donor (HD), by
flow cytometry assay with a mouse antibody specific for human IFNγR1, and an isotype control. (B) The p-STAT1 level expression (measured as MFI), to analyze
IFNγR1-mediated signaling, is detected by flow cytometry assay with a mouse antibody specific for human p-STAT1, and an isotype control, after incubation with
IFN-γ (1,000 UI/ml) for 30min, or medium alone, in CD14-positive mononuclear blood cells in the patient (P1) and a healthy donor (HD).
Frontiers in Immunology | www.frontiersin.org 4 June 2020 | Volume 11 | Article 1161
Dotta et al. DCs Depletion in IFNγR1 Deficiency
FIGURE 2 | Functional analysis of 818del4 mutated IFNγR1 and study of patient’s DCs. (A) Percentage of plasmacytoid dendritic cells (%pDCs) and myeloid dendritic
cells (%mDCs) in P1 in timing (months) of therapy and follow-up (the dotted lines indicate the normal values, gray-colored for mDCs and black-colored for pDCs).
IFN-α (B) and CXCL10 production (C) are measured in triplicate, by freshly isolated PBMCs after stimulation for 24 h with 6 mg/ml CpG, HSV-1 (copies/200ml), or
medium alone, in the patient (P1) and a healthy donor (HD). Statistical analysis by non-parametric test shows a significant difference (*p < 0.05, **p < 0.01, ***p <
0.001). (D) Plasmacytoid dendritic cells (%pDCs) and myeloid dendritic cells (%mDCs) are analyzed in other patients with mycobacterial infection: P2 has AD partial
IFNγR1 deficiency and had acute mycobacterial infection during the evaluation of flow cytometry, while P3 has AD partial IFNγR1 deficiency but blood was collected
when he was free of infection; P4, P5, and P6 presented a mycobacterial infection without any identified predisposing genetic cause (the dotted lines indicate the
normal values, gray-colored for mDCs and black-colored for pDCs).
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FIGURE 3 | Study of 818del4 mutated DCs maturation pattern. DCs are
cultured for 24 h with LPS for both the patient (P1) and a healthy donor (HD)
and the expression of DCs maturation markers (HLA-DR, CD80, CD83, CD86)
are analyzed by flow cytometry, together with an isotype control (PE- or
PerCP- IgG): a similar pattern of maturation is present in both the patient and
the healthy subject.
Pakistani non-consanguineous parents; her past medical history
was uneventful, and the family history was unremarkable.
She had not received BCG vaccine, nor had never been to
Pakistan. At admission, her blood tests revealed microcytic
anemia (Hb 6.5 g/dl, MCV 60.9 fl, RDW 19.4%), raised
C-reactive protein (CRP 125 mg/L, range <5 mg/L) and
procalcitonin (9.2 ng/ml, range <0.1 ng/ml), leukocytosis (WBC
21,600 cells/mmc) with neutrophilia (ANC 17,170 cells/mmc).
She had normal lymphocyte count (ALC 3,230 cells/mmc), and
monocyte count at the lower range (AMC 230 cells/mmc).
On physical examination, she had mild spleen enlargement.
The abdomen ultrasound and the computed tomography-scan
revealed a spleen length of 8 cm [mean of normal age-related
spleen size from 6.8 to 7.5 cm (11)] with multiple dishomogenous
areas, slight hepatomegaly, without focal lesions, and multiple
mediastinal and mesenteric lymph nodes showing internal
colliquation. The infectious disease screening included blood
cultures, Brucella, Rickettsia, Bartonella, Coxiella, Leishmania,
Toxoplasma, Plasmodium, Herpesviruses, Epstein-Barr virus, and
HIV serology, all tested negative. The Mantoux tuberculin skin
test read after 48 h resulted on induration of 5mm, while
the QuantiFERON-TB Gold tested negative. She underwent
a laparoscopic biopsy of an abdomen lymph node (20 ×
14mm) that showed a necrotizing granulomatous lymphadenitis
with focal colliquation and the Mycobacterium avium was
detected by PCR assay. The patient was commenced with the
association therapy of clarithromycin, ethambutol and rifabutin,
the latter discontinued after 6 months because of an acute
drug-related uveitis. The dual therapy with clarithromycin
and ethambutol was continued for 18 months. The patient
fully recovered. At onset, routine immunological tests revealed
slightly elevated levels of serum immunoglobulin (Ig) M
(IgG 1,220 mg/dl -range 462–1,710 mg/dl-, IgA 167 mg/dl
-range 27–173 mg/dl-, IgM 465 mg/dl -range 62–257 mg/dl-),
and IgE (575 range KU/L -range <140 KU/L-), normal
neutrophil respiratory burst assay, and normal bone marrow
aspirate. The analysis of the lymphocytes subsets displayed a
prevalence of effector T and B cells, an increased proportion
of activated HLA-DR+ T cells, and reduction of NK cell
percentages (CD16+CD56+ 2.7%/90 cells/mmc, normal range
5–28.4%/100–1,000 cells/mmc) (Table 1).
IFNGR1 gene sequencing revealed a heterozygous small
deletion in the exon 6, the c.819_822delTAAT (p.N274Hfs∗2).
This mutation is already reported as responsible of AD partial
IFNγR1 deficiency (7). The flow cytometry analysis of IFNγR1
expression on patient’s monocytes showed that the receptor
was present at a higher level on cell’s surface (Figures 1A,B),
while STAT1 phosphorylation (pY-701) following stimulation
with IFNγ was markedly reduced, as compared to the healthy
control (Figures 1C,D).
Study of DCs Counts Revealed a Depletion
of Circulating and Tissular Subsets
Analysis of DCs was performed based on specific cell surface
markers. Myeloid/classical DCs (mDCs) express typical myeloid
antigens (CD11c, CD13, CD33, CD11b) with the majority of
them expressing CD1c/BDCA1, while plasmacytoid DCs (pDCs)
express CD123, CD303/BDCA2, CD304/BDCA4, and produces
IFNα after activation with CpG or viral infection (12–16). At
the time of P1 mycobacterial infection diagnosis, we observed
a marked reduction of pDCs equal to 0.04%/143 cells/mmc
(normal range 0.16–0.76%) and of mDCs equal to 0.05%/179
cells/mmc (normal range 0.18–0.92%) (Table 1). Monitoring
of DCs subsets during the infection treatment showed that
the percentage of DCs progressively increased, reverting to
the normal levels by the end of the treatment (18 months)
and remaining normal in the following months (Figure 2A).
In addition, ELISA measurements of IFNα and CXCL10 in
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FIGURE 4 | Abdominal lymph node histology. Sections are from lymph nodes of P1 (A–D) and two age-matched control (E–L) with mycobacterial infection, stained
as labeled. On H&E, necrotizing granulomas are surrounded by lymphoid cells represented by CD20+ B-cells and CD3+ T-cells. CD303/BDCA2+ pDC are severely
reduced as compared to matched controls. Original magnification: 40x (A–C,E–G,I–K; scale bar 500µm), 100x (D,H,L; scale bar 200µm).
24-h supernatants of PBMCs incubated with CpG or with
increasing copies of humanHerpes Simplex Virus Type 1 (HSV1)
demonstrated lower levels of these cytokines in P1 as compared
to the healthy control (Figures 2B,C), which is in accord with the
blood depletion of pDCs.
Next, we compared DCs subsets in other two patients (P2
and P3) with AD partial IFNγR1 deficiency, in P2 during a
mycobacterial infection, while P3 was free of acute mycobacterial
infection at the time the blood sample was collected. We also
analyzed DCs in three other patients that had a mycobacterial
cervical lymphadenopathy but still without any evidence of
genetic mutations associated with MSMD. We detected a low
number of both pDCs andmDCs subsets in P2, while DCs counts
were normal in all the other investigated patients (Figure 2D).
Finally, in P1, we studied DCs maturation by flow cytometry: the
analysis of HLA-DR, CD80, CD83, and CD86 markers revealed
that, after 24 h of in vitro culture with LPS, DCs exhibited a
normal pattern of maturation (Figure 3).
The Study of the Mycobacteria-Infected
Lymph Node Biopsy Revealed pDCs
Depletion
In P1, the analysis of the lymph node biopsy revealed a
granulomatous necrotizing lymphadenitis with BDCA2+
plasmacytoid dendritic cells reduction (Figures 4A–E),
as compared with other age-matched granulomatous
lymphadenitis of mycobacterial origin derived from control
subjects (Figures 4F–L); the distribution of CD20+ B-cells and
CD3+ T-cells of the nodal parenchyma was normal.
DISCUSSION
Immature DCs circulating in the peripheral blood can recognize
and internalize pathogens for antigen presentation to T
lymphocytes. Upon activation, DCs undergo maturation, secrete
T cell activating cytokines such as IL-12, and migrate to lymph
nodes where they have an essential role in orchestrating the host
defense (11–15). In recent years, the identification of patients
with DCs deficiency has allowed the investigation of the cellular
pathways and genetic regulation of DCs haematopoiesis and
their complex role in both innate and adaptive immunity.
DCs deficiency (in both myeloid and plasmocytoid subsets)
has been reported in patients with heterozygous germline
GATA2 mutations, a heterogeneous disorder characterized by
familial myelodysplasia/acute myeloid leukemia (MSD/AML),
the MonoMac (monocytopenia with Mycobacterium avium
complex) syndrome, and/or the Emberger syndrome (primary
lymphedema and MSD/AML) (17). In patients with Interferon
Regulator Factor (IRF) eight mutations the AR variant causes
a complete lack of circulating monocytes and DCs, while
the AD variant associates with a selective depletion of
CD11c+CD1c+ circulating dendritic cells (18, 19), as reported
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also in patients with the recently described SPPL2A (signal
peptide peptidase-like 2A) deficiency, where a defective IL-12
and IL-23 production by mDCs may disrupt the priming of T
lymphocytes (19, 20). Other disorders may display pancytopenia
with monocyte and DCs deficiencies, from the WHIM (warts,
hypogammaglobulinemia, infections, myelokathexis) syndrome
(21), to defects in genes related to DCs development and
functions, such as the CD40/CD40L deficiency, the MCH class
II deficiency, the Wiskott-Aldrich syndrome, the Pitt-Hopkins
Syndrome, or the IRF7 deficiency (22). The activation of DCs
depends upon a crosstalk with CD4+ T lymphocytes, enabling
the same DCs to prime cytotoxic T lymphocytes, polarize
a Th1T cells response, and regulate the immunity against
intracellular pathogens (23–25). In lymph nodes, the T-cell
response requires contact-dependent interaction with DCs, in
order to activate cytokine production and cellular proliferation
(26). Miro et al. investigated the T cell-driven maturation
of DCs in a human in vitro model and supported how the
secretion of IL-12 by DCs is dependent upon co-stimulatory
stimuli, the CD40-CD40L-interaction during a direct cell-cell
contact with CD4+ T cells, and the IFNγ production by T
cells, in the presence of the antigen (27). Meanwhile, DCs
maturation and activation requires T cell response to IL-12
and IFNγ: defect in the IL12β1R receptor prevents IL-12-
mediated signaling and impairs both the expression of DCs
maturation markers and the DCs production of IL-12. Moreover,
the IFNγ receptor response in T cells is required for a functional
interaction with DCs, likely through the STAT1-dependent IL-
12R β2 expression on T cells via IFNγ signaling (28). Herein,
we report the case of a de novo AD partial IFNγR1 deficiency
that onset in early childhood as disseminated lymphadenitis
due to Mycobacterium avium, well-responding to a treatment
with clarithromycin and ethambutol. The acute phase of the
mycobacterial infection associated with a marked reduction
of both mDCs and pDCs, as measured in the peripheral
blood. In addition, lymph node biopsy analysis demonstrated
a profound decrease of pDCs also in the lymphoid tissue. It
has been reported that DCs are decreased in HIV (29), in the
most severe form of dengue fever (30), and in patients with
active tuberculosis (TB), where it is associated an impaired
IFNα production (31). Particularly, it was observed a more
significant reduction of pDCs both in the pulmonary and
extrapulmonary forms of TB, while mDCs count was lower in the
extrapulmonary form of TB. It has been showed that DC counts
can increase during highly active antiretroviral therapy and
normalize after anti-tuberculous therapy in responder patients.
Similarly, in our patient DCs subsets progressively increased
and normalized after the end of the 18-months therapy. In
addition, evaluation of DCsmaturation in vitro appeared normal,
thus suggesting that circulating mDCs and pDCs depletion
during the active mycobacterial infection may not be related to
abnormal generation of these cell types. Conversely, a disrupted
DCs trafficking or increased DCs apoptosis due to the defective
IFNγR1-mediated signaling might account for DCs depletion
during mycobacterial infection. Further studies will allow to
elucidate DCs role in response against mycobacterial disease and
evaluate the DC counts as a diagnostic tool to monitor treatment
response or to predict development of mycobacterial infection in
patients with inborn errors of IFNγ immunity.
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